Long‐term effect of interferon alpha‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis
Chien‐Hui Hung(Kaohsiung Chang Gung Memorial Hospital), C.‐S. Changchien(Center for HIV and Hepatogastroenterology), Hung‐Da Tung(Center for HIV and Hepatogastroenterology), Tsung‐Hui Hu(National Sun Yat-sen University), J.‐H. Wang(Center for HIV and Hepatogastroenterology), Chia‐Hsiang Chen(Center for HIV and Hepatogastroenterology), C.‐M. Lee(Center for HIV and Hepatogastroenterology), Wei‐Jen Chen(Kaohsiung Chang Gung Memorial Hospital), Sheng‐Nan Lu(Kaohsiung Chang Gung Memorial Hospital)
Cited by 116
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan
|Gastroenterology|2008|547
Hepatogastroenterology
|Hepatogastroenterology|2012|536